Celldex Therapeutics Operating Income 2010-2022 | CLDX

Celldex Therapeutics operating income from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Celldex Therapeutics Annual Operating Income
(Millions of US $)
2021 $-71
2020 $-63
2019 $-55
2018 $-156
2017 $-122
2016 $-133
2015 $-130
2014 $-122
2013 $-81
2012 $-58
2011 $-43
2010 $-6
2009 $-37
Celldex Therapeutics Quarterly Operating Income
(Millions of US $)
2022-03-31 $-23
2021-12-31 $-20
2021-09-30 $-21
2021-06-30 $-13
2021-03-31 $-17
2020-12-31 $-25
2020-09-30 $-14
2020-06-30 $-11
2020-03-31 $-13
2019-12-31 $-13
2019-09-30 $-12
2019-06-30 $-12
2019-03-31 $-18
2018-12-31 $-12
2018-09-30 $-8
2018-06-30 $-17
2018-03-31 $-120
2017-12-31 $-26
2017-09-30 $-32
2017-06-30 $-29
2017-03-31 $-35
2016-12-31 $-35
2016-09-30 $-30
2016-06-30 $-32
2016-03-31 $-36
2015-12-31 $-33
2015-09-30 $-32
2015-06-30 $-33
2015-03-31 $-31
2014-12-31 $-32
2014-09-30 $-30
2014-06-30 $-29
2014-03-31 $-31
2013-12-31 $-22
2013-09-30 $-23
2013-06-30 $-19
2013-03-31 $-17
2012-12-31 $-17
2012-09-30 $-15
2012-06-30 $-13
2012-03-31 $-13
2011-12-31 $-12
2011-09-30 $-11
2011-06-30 $-10
2011-03-31 $-10
2010-12-31 $21
2010-09-30 $-9
2010-06-30 $-9
2010-03-31 $-9
2009-12-31 $-13
2009-09-30 $-7
2009-06-30 $-9
2009-03-31 $-8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.262B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00